Analysts Set Pyxis Oncology, Inc. (NASDAQ:PYXS) Price Target at $7.50

Posted by on Sep 12th, 2026

Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the ten ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $8.75.

PYXS has been the subject of a number of research reports. Wedbush upped their target price on shares of Pyxis Oncology from $6.00 to $8.00 and gave the stock an “outperform” rating in a research report on Thursday. Wall Street Zen downgraded Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings lowered Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Wells Fargo & Company raised their price target on Pyxis Oncology from $12.00 to $19.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, HC Wainwright lifted their price objective on Pyxis Oncology from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Thursday.

Get Our Latest Report on PYXS

Institutional Investors Weigh In On Pyxis Oncology

A number of hedge funds have recently bought and sold shares of the business. Maia Wealth LLC bought a new position in Pyxis Oncology during the fourth quarter valued at $25,000. Engineers Gate Manager LP bought a new stake in shares of Pyxis Oncology in the 4th quarter worth about $26,000. Fox Run Management L.L.C. bought a new stake in shares of Pyxis Oncology in the 4th quarter worth about $26,000. XTX Topco Ltd purchased a new stake in shares of Pyxis Oncology during the 2nd quarter valued at about $40,000. Finally, LPL Financial LLC raised its position in shares of Pyxis Oncology by 150.7% during the 4th quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock valued at $40,000 after buying an additional 21,100 shares in the last quarter. Hedge funds and other institutional investors own 39.07% of the company’s stock.

Pyxis Oncology Price Performance

PYXS stock opened at $3.21 on Wednesday. Pyxis Oncology has a 1-year low of $1.03 and a 1-year high of $5.55. The company has a market capitalization of $267.75 million, a price-to-earnings ratio of -2.28 and a beta of 1.34. The business has a 50 day simple moving average of $3.03 and a two-hundred day simple moving average of $2.24.

Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Sell-side analysts anticipate that Pyxis Oncology will post -1.21 EPS for the current fiscal year.

About Pyxis Oncology

(Get Free Report)

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.

Featured Stories

Analyst Recommendations for Pyxis Oncology (NASDAQ:PYXS)

Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.